Those patients whose cancers were positive for phosphorylated p53 and who received either adjuvant hormonal or adjuvant chemo-plus hormonal therapy had a significantly shorter duration of survival (P=0.003 and 0.026 respectively). This evidence concerns the gene TP53 and cancer.